Biological ||| S:0 E:10 ||| NNP
,  ||| S:10 E:12 ||| ,
nutritional  ||| S:12 E:24 ||| NN
and  ||| S:24 E:28 ||| CC
clinical  ||| S:28 E:37 ||| JJ
aspects  ||| S:37 E:45 ||| NNS
of  ||| S:45 E:48 ||| IN
feeding  ||| S:48 E:56 ||| VBG
preterm  ||| S:56 E:64 ||| JJ
infants  ||| S:64 E:72 ||| NNS
with  ||| S:72 E:77 ||| IN
human  ||| S:77 E:83 ||| JJ
milk  ||| S:83 E:88 ||| NN
Benefits  ||| S:88 E:97 ||| NNS
of  ||| S:97 E:100 ||| IN
breastfeeding  ||| S:100 E:114 ||| NNS
are  ||| S:114 E:118 ||| VBP
widely  ||| S:118 E:125 ||| RB
recognized ||| S:125 E:135 ||| VBN
,  ||| S:135 E:137 ||| ,
during  ||| S:137 E:144 ||| IN
the  ||| S:144 E:148 ||| DT
last  ||| S:148 E:153 ||| JJ
decades  ||| S:153 E:161 ||| NNS
human  ||| S:161 E:167 ||| JJ
milk  ||| S:167 E:172 ||| NN
has  ||| S:172 E:176 ||| VBZ
been  ||| S:176 E:181 ||| VBN
identified  ||| S:181 E:192 ||| VBN
as  ||| S:192 E:195 ||| IN
the  ||| S:195 E:199 ||| DT
normative  ||| S:199 E:209 ||| JJ
standard  ||| S:209 E:218 ||| NN
for  ||| S:218 E:222 ||| IN
infant  ||| S:222 E:229 ||| JJ
feeding  ||| S:229 E:237 ||| NN
and  ||| S:237 E:241 ||| CC
nutrition ||| S:241 E:250 ||| NN
.  ||| S:250 E:252 ||| .
Recent  ||| S:252 E:259 ||| JJ
evidence  ||| S:259 E:268 ||| NN
focused  ||| S:268 E:276 ||| VBN
on  ||| S:276 E:279 ||| IN
specific  ||| S:279 E:288 ||| JJ
bioactive  ||| S:288 E:298 ||| NN
and  ||| S:298 E:302 ||| CC
immunomodulatory  ||| S:302 E:319 ||| JJ
factors ||| S:319 E:326 ||| NNS
,  ||| S:326 E:328 ||| ,
such  ||| S:328 E:333 ||| JJ
as  ||| S:333 E:336 ||| IN
oligosaccharides ||| S:336 E:352 ||| NN
,  ||| S:352 E:354 ||| ,
lactose ||| S:354 E:361 ||| NN
,  ||| S:361 E:363 ||| ,
glycosaminoglycans  ||| S:363 E:382 ||| VBG
of  ||| S:382 E:385 ||| IN
human  ||| S:385 E:391 ||| JJ
milk  ||| S:391 E:396 ||| NN
and  ||| S:396 E:400 ||| CC
the  ||| S:400 E:404 ||| DT
variability  ||| S:404 E:416 ||| NN
of  ||| S:416 E:419 ||| IN
their  ||| S:419 E:425 ||| PRP$
concentrations  ||| S:425 E:440 ||| NNS
during  ||| S:440 E:447 ||| IN
lactation  ||| S:447 E:457 ||| NN
in  ||| S:457 E:460 ||| IN
both  ||| S:460 E:465 ||| DT
term  ||| S:465 E:470 ||| NN
and  ||| S:470 E:474 ||| CC
preterm  ||| S:474 E:482 ||| JJ
milk ||| S:482 E:486 ||| NN
.  ||| S:486 E:488 ||| .
Human  ||| S:488 E:494 ||| JJ
milk  ||| S:494 E:499 ||| NN
should  ||| S:499 E:506 ||| MD
be  ||| S:506 E:509 ||| VB
fortified  ||| S:509 E:519 ||| VBN
with  ||| S:519 E:524 ||| IN
proteins ||| S:524 E:532 ||| NNS
,  ||| S:532 E:534 ||| ,
minerals  ||| S:534 E:543 ||| NNS
and  ||| S:543 E:547 ||| CC
vitamins  ||| S:547 E:556 ||| JJ
to  ||| S:556 E:559 ||| TO
ensure  ||| S:559 E:566 ||| VB
optimal  ||| S:566 E:574 ||| JJ
nutrient  ||| S:574 E:583 ||| JJ
intake  ||| S:583 E:590 ||| NN
for  ||| S:590 E:594 ||| IN
preterm  ||| S:594 E:602 ||| JJ
VLBWI  ||| S:602 E:608 ||| NN
infants ||| S:608 E:615 ||| NNS
.  ||| S:615 E:617 ||| .
Best  ||| S:617 E:622 ||| JJS
fortification  ||| S:622 E:636 ||| JJ
strategies  ||| S:636 E:647 ||| NNS
as  ||| S:647 E:650 ||| IN
well  ||| S:650 E:655 ||| RB
as  ||| S:655 E:658 ||| IN
the  ||| S:658 E:662 ||| DT
optimal  ||| S:662 E:670 ||| JJ
composition  ||| S:670 E:682 ||| NN
of  ||| S:682 E:685 ||| IN
fortifiers  ||| S:685 E:696 ||| NNS
are  ||| S:696 E:700 ||| VBP
still  ||| S:700 E:706 ||| RB
object  ||| S:706 E:713 ||| VB
of  ||| S:713 E:716 ||| IN
research ||| S:716 E:724 ||| NN
.  ||| S:724 E:726 ||| .
Short  ||| S:726 E:732 ||| JJ
and  ||| S:732 E:736 ||| CC
long-term  ||| S:736 E:746 ||| JJ
clinical ||| S:746 E:754 ||| JJ
,  ||| S:754 E:756 ||| ,
metabolic ||| S:756 E:765 ||| NN
,  ||| S:765 E:767 ||| ,
immunologic  ||| S:767 E:779 ||| NN
and  ||| S:779 E:783 ||| CC
neurodevelopmental  ||| S:783 E:802 ||| JJ
advantages  ||| S:802 E:813 ||| NNS
of  ||| S:813 E:816 ||| IN
breastfeeding  ||| S:816 E:830 ||| JJ
ndividualizes  ||| S:830 E:844 ||| JJ
fortification  ||| S:844 E:858 ||| NN
-  ||| S:858 E:860 ||| :
particulary  ||| S:860 E:872 ||| JJ
adjustable  ||| S:872 E:883 ||| JJ
fortification-  ||| S:883 E:898 ||| NN
has  ||| S:898 E:902 ||| VBZ
proven  ||| S:902 E:909 ||| VBN
to  ||| S:909 E:912 ||| TO
be  ||| S:912 E:915 ||| VB
effective  ||| S:915 E:925 ||| JJ
when  ||| S:925 E:930 ||| WRB
compared  ||| S:930 E:939 ||| VBN
to  ||| S:939 E:942 ||| TO
formula  ||| S:942 E:950 ||| NN
are  ||| S:950 E:954 ||| VBP
well  ||| S:954 E:959 ||| RB
documented ||| S:959 E:969 ||| VBN
.  ||| S:969 E:971 ||| .
Moreover  ||| S:971 E:980 ||| RB
several  ||| S:980 E:988 ||| JJ
non-experimental  ||| S:988 E:1005 ||| JJ
studies  ||| S:1005 E:1013 ||| NNS
observed  ||| S:1013 E:1022 ||| VBD
that  ||| S:1022 E:1027 ||| DT
clinical  ||| S:1027 E:1036 ||| JJ
feeding  ||| S:1036 E:1044 ||| NN
tolerance  ||| S:1044 E:1054 ||| NN
is  ||| S:1054 E:1057 ||| VBZ
improved  ||| S:1057 E:1066 ||| VBN
and  ||| S:1066 E:1070 ||| CC
the  ||| S:1070 E:1074 ||| DT
attainment  ||| S:1074 E:1085 ||| NN
of  ||| S:1085 E:1088 ||| IN
full  ||| S:1088 E:1093 ||| JJ
enteral  ||| S:1093 E:1101 ||| JJ
feeding  ||| S:1101 E:1109 ||| NN
is  ||| S:1109 E:1112 ||| VBZ
quicker  ||| S:1112 E:1120 ||| JJR
by  ||| S:1120 E:1123 ||| IN
a  ||| S:1123 E:1125 ||| DT
diet  ||| S:1125 E:1130 ||| NN
of  ||| S:1130 E:1133 ||| IN
human  ||| S:1133 E:1139 ||| JJ
milk ||| S:1139 E:1143 ||| NN
.  ||| S:1143 E:1145 ||| .
In  ||| S:1145 E:1148 ||| IN
addition ||| S:1148 E:1156 ||| NN
,  ||| S:1156 E:1158 ||| ,
benefits  ||| S:1158 E:1167 ||| NNS
of  ||| S:1167 E:1170 ||| IN
breastfeeding  ||| S:1170 E:1184 ||| NN
on  ||| S:1184 E:1187 ||| IN
psychological  ||| S:1187 E:1201 ||| JJ
and  ||| S:1201 E:1205 ||| CC
relational  ||| S:1205 E:1216 ||| JJ
aspects  ||| S:1216 E:1224 ||| NNS
have  ||| S:1224 E:1229 ||| VBP
to  ||| S:1229 E:1232 ||| TO
be  ||| S:1232 E:1235 ||| VB
considered ||| S:1235 E:1245 ||| VBN
.  ||| S:1245 E:1247 ||| .
MotherÂ’s  ||| S:1247 E:1256 ||| NNP
own  ||| S:1256 E:1260 ||| JJ
milk  ||| S:1260 E:1265 ||| NN
remains  ||| S:1265 E:1273 ||| VBZ
the  ||| S:1273 E:1277 ||| DT
first  ||| S:1277 E:1283 ||| JJ
choice  ||| S:1283 E:1290 ||| NN
for  ||| S:1290 E:1294 ||| IN
all  ||| S:1294 E:1298 ||| DT
neonates ||| S:1298 E:1306 ||| NN
,  ||| S:1306 E:1308 ||| ,
when  ||| S:1308 E:1313 ||| WRB
it  ||| S:1313 E:1316 ||| PRP
is  ||| S:1316 E:1319 ||| VBZ
not  ||| S:1319 E:1323 ||| RB
available  ||| S:1323 E:1333 ||| JJ
or  ||| S:1333 E:1336 ||| CC
not  ||| S:1336 E:1340 ||| RB
sufficient  ||| S:1340 E:1351 ||| JJ
despite  ||| S:1351 E:1359 ||| IN
significant  ||| S:1359 E:1371 ||| JJ
lactation  ||| S:1371 E:1381 ||| JJ
support ||| S:1381 E:1388 ||| NN
,  ||| S:1388 E:1390 ||| ,
donor  ||| S:1390 E:1396 ||| JJ
milk  ||| S:1396 E:1401 ||| NN
represents  ||| S:1401 E:1412 ||| VBZ
the  ||| S:1412 E:1416 ||| DT
second  ||| S:1416 E:1423 ||| JJ
best  ||| S:1423 E:1428 ||| JJS
alternative  ||| S:1428 E:1440 ||| NN
and  ||| S:1440 E:1444 ||| CC
although  ||| S:1444 E:1453 ||| IN
some  ||| S:1453 E:1458 ||| DT
nutritional  ||| S:1458 E:1470 ||| JJ
elements  ||| S:1470 E:1479 ||| NNS
are  ||| S:1479 E:1483 ||| VBP
inactivated  ||| S:1483 E:1495 ||| VBN
by  ||| S:1495 E:1498 ||| IN
the  ||| S:1498 E:1502 ||| DT
pasteurization  ||| S:1502 E:1517 ||| JJ
process ||| S:1517 E:1524 ||| NN
,  ||| S:1524 E:1526 ||| ,
it  ||| S:1526 E:1529 ||| PRP
still  ||| S:1529 E:1535 ||| RB
has  ||| S:1535 E:1539 ||| VBZ
documented  ||| S:1539 E:1550 ||| VBN
advantages  ||| S:1550 E:1561 ||| NNS
compared  ||| S:1561 E:1570 ||| VBN
to  ||| S:1570 E:1573 ||| TO
formula ||| S:1573 E:1580 ||| NN
.  ||| S:1580 E:1582 ||| .
